Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment

The joint studies showed some improvement in a few biological measures of the disease, but most of the changes were small and not enough to make a difference in delaying cognitive decline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qikjFVD
via IFTTT